Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
An announcement from AIM ImmunoTech ( (AIM) ) is now available.
AIM ImmunoTech announced that Thomas K. Equels and Peter W. Rodino III have decided to forego their entitled cash bonuses for 2024. This decision aims to allocate more financial resources towards the company’s Ampligen research and development activities, reflecting a strategic move to prioritize long-term growth and innovation over immediate compensation.
More about AIM ImmunoTech
YTD Price Performance: -56.72%
Average Trading Volume: 448,657
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $12.12M
Find detailed analytics on AIM stock on TipRanks’ Stock Analysis page.
